Estrogen receptor and HER2 status on disseminated tumor cells and primary tumor in patients with early breast cancer

Translational Oncology

Volumn 8, Issue 6, 2015, Pages 509-516

  Jäger, Bernadette A S ^a,d   Finkenzeller, Charlotte ^b   Bock, Carolin ^b   Majunke, Leonie ^b   Jueckstock, Julia K ^b   Andergassen, Ulrich ^b   Neugebauer, Julia K ^b   Pestka, Aurelia ^b   Friedl, Thomas W P ^a   Jeschke, Udo ^b   Janni, Wolfgang ^a   Doisneau Sixou, Sophie F ^b,c   Rack, Brigitte K ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ARTICLE; BONE MARROW BIOPSY; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER DIAGNOSIS; CELL ISOLATION; CONTROLLED STUDY; FLUORESCENCE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; METASTASIS; MOLECULARLY TARGETED THERAPY; PILOT STUDY; PRIMARY TUMOR; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

EID: 84949746367     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2015.11.009     Document Type: Article

References (36)

1. Pantel K and Woelfle U (2004). Micrometastasis in breast cancer and other solid tumors. J Biol Regul Homeost Agents 18, 120-125.
2. Chiang AC and Massagué J (2008). Molecular basis of metastasis. N Engl J Med 359, 2814-2823. http://dx.doi.org/10.1056/NEJMra0805239.
3. Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A, and Jackson S, et al (2010). Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer 116, 3330-3337. http://dx.doi.org/10.1002/cncr.25145.
4. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, and Gebauer G, et al (2005). A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353, 793-802. http: //dx.doi.org/10.1056/NEJMoa050434.
5. Falck AK, Bendahl PO, Ingvar C, Isola J, Jönsson PE, Lindblom P, Lövgren K, Rennstam K, Fernö M, and Rydén L (2012). Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study. BMC Cancer 12, 403. http: //dx.doi.org/10.1186/1471-2407-12-403.
6. Krawczyk N, Banys M, Neubauer H, Solomayer EF, Gall C, Hahn M, Becker S, Bachmann R, Wallwiener D, and Fehm T (2009). HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res 29, 4019-4024.
7. Bidard FC, Vincent-Salomon A, Gomme S, Nos C, de Rycke Y, Thiery JP, Sigal-Zafrani B, Mignot L, Sastre-Garau X, and Pierga JY (2008). Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and localrelapse. Clin Cancer Res 14, 3306-3311. http://dx.doi.org/10.1158/1078-0432.CCR-07-4749.
8. Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF,Wallwiener D, Kimmig R, and Kasimir-Bauer S (2009).Detection and characterization of circulating tumor cells in blood of primary breast cancer patients byRT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 11, R59. http://dx.doi.org/10. 1186/bcr2349.
9. Braun S, Kentenich C, JanniW,Hepp F, deWaal J,Willgeroth F, SommerH, and Pantel K (2000). Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bonemarrowof high-risk breast cancer patients. J Clin Oncol 18, 80-86.
10. Fehm T, Mueller V, Marches R, Klein G, Gueckel B, Neubauer H, Solomayer E, and Becker S (2008). Tumor cell dormancy: implications for the biology and treatment of breast cancer. APMIS 116, 742-753. http://dx.doi.org/10.1111/ j.1600-0463.2008.01047.x.
11. Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Juckstock J, Borgen E, Rack B, Braun S, and Sommer H, et al (2011). Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse-a European pooled analysis. Clin Cancer Res 17, 2967-2976.
12. Mathiesen RR, Borgen E, Renolen A, Løkkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, and Mjaaland I, et al (2012). Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Res 14, R117. http: //dx.doi.org/10.1186/bcr3242.
13. Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O'Malley FP, Miller N, Andrulis IL, Brenner DM, and Clemons MJ (2009). Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 29, 1557-1562.
14. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, and Hadary A (2005). Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 93, 552-556. http://dx.doi.org/10.1038/sj.bjc.6602738.
15. Fehm T, Krawczyk N, Solomayer EF, Becker-Pergola G, Duerr-Stoerzer S, Neubauer H, Seeger H, Staebler A, Wallwiener D, and Becker S (2008). ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res 10, R76. http://dx.doi.org/10.1186/bcr2143.
16. Solomayer EF, Becker S, Pergola-Becker G, Bachmann R, Kramer B, Vogel U, Neubauer H, Wallwiener D, Huober J, and Fehm TN (2006). Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat 98, 179-184.
17. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, BlandKI, Borgen PI,Clark G, Edge SB, and HayesDF (2002).Revision of the American JointCommittee onCancer staging system for breast cancer. J Clin Oncol 20, 3628-3636.
18. RemmeleWand Stegner HE (1987). Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8, 138-140.
19. Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, and Naume B, et al (2006). A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 107, 885-892. http://dx.doi.org/10.1002/cncr.22076.
20. Bock C, Rack B, Kuhn C, Hofmann S, Finkenzeller C, Jäger B, Jeschke U, and Doisneau-Sixou SF (2012). Heterogeneity of ERα and ErbB2 status in cell lines and circulating tumor cells of metastatic breast cancer patients. Transl Oncol 5, 475-485.
21. Hartkopf AD, Banys M, Meier-Stiegen F, Hahn M, Rohm C, Hoffmann J, Helms G, Taran FA, Wallwiener M, and Walter C, et al (2013). The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse. Breast Cancer Res Treat 138, 509-517.
22. Becker S, Becker-Pergola G, Fehm T, Wallwiener D, and Solomayer E-F (2005). Her2 expression on disseminated tumor cells from bone marrow of breast cancer patients. Anticancer Res 25, 2171-2175.
23. Krishnamurthy S, Bischoff F, AnnMayer J,Wong K, Pham T, KuererH, Lodhi A, Bhattacharyya A, Hall C, and Lucci A (2013). Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer. Cancer Med 2, 226-233. http://dx.doi.org/10.1002/cam4.70.
24. Fehm T, Becker S, Becker-Pergola G, Sotlar K, Gebauer G, Duerr-Stoerzer S, Neubauer H, Wallwiener D, and Solomayer EF (2006). Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer. Breast Cancer Res 8, R60. http: //dx.doi.org/10.1186/bcr1611.
25. Quintela-Fandino M, López JM, Hitt R, Gamarra S, Jimeno A, Ayala R, Hornedo J, Guzman C, Gilsanz F, and Cortés-Funes H (2006). Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. J Clin Oncol 24, 3611-3618. http://dx.doi.org/10.1200/JCO.2005.04.0576.
26. Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmüller G, and Pantel K (2001). ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 61, 1890-1895.
27. Hüsemann Y,Geigl JB, Schubert F,Musiani P,MeyerM,Burghart E, ForniG, EilsR, Fehm T, and Riethmüller G, et al (2008). Systemic spread is an early step in breast cancer. Cancer Cell 13, 58-68. http://dx.doi.org/10.1016/j.ccr.2007.12.003.
28. Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH, and Cote RJ (2006). Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stemcell phenotype. Clin Cancer Res 12, 5615-5621. http://dx.doi.org/10.1158/1078-0432.CCR-06-0169.
29. Marsden CG, Wright MJ, Carrier L, Moroz K, and Rowan BG (2012). Disseminated breast cancer cells acquire a highly malignant and aggressive metastatic phenotype during metastatic latency in the bone. PLoS One 7, e47587. http://dx.doi.org/10.1371/journal.pone.0047587.
30. Rack B, Jückstock J, Günthner-Biller M, Andergassen U, Neugebauer J, Hepp P, Schoberth A, Mayr D, Zwingers T, and Schindlbeck C, et al (2012). Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. Arch Gynecol Obstet 285, 485-492. http: //dx.doi.org/10.1007/s00404-011-1954-2.
31. Rack B, Jückstock J, Genss EM, Schoberth A, Schindlbeck C, Strobl B, Heinrigs M, Rammel G, Zwingers T, and Sommer H, et al (2010). Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 30, 1807-1813.
32. BozionellouV,MavroudisD, PerrakiM, Papadopoulos S, Apostolaki S, Stathopoulos E, Stathopoulou A, Lianidou E, and Georgoulias V (2004). Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 10, 8185-8194. http://dx.doi.org/10.1158/1078-0432.CCR-03-0094.
33. Vincent-Salomon A, Bidard FC, and Pierga JY (2008).Bonemarrowmicrometastasis in breast cancer: review of detectionmethods, prognostic impact and biological issues. J Clin Pathol 61, 570-576. http://dx.doi.org/10.1136/jcp.2007.046649.
34. Tjensvoll K, Oltedal S, Heikkilä R, Kvaløy JT, Gilje B, Reuben JM, Smaaland R, and Nordgård O (2012). Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome. BMC Cancer 12, 190. http://dx.doi.org/10.1186/1471-2407-12-190.
35. Riethdorf S and Pantel K (2008). Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. Pathobiology 75, 140-148. http://dx.doi.org/10.1159/000123852.
36. Vincent-Salomon A, Pierga J-Y, Couturier J, d'Enghien CD, Nos C, Sigal-Zafrani B, Lae M, Fréneaux P, Diéras V, and Thiéry P, et al (2007). HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? Br J Cancer 96, 654-659. http://dx.doi.org/10.1038/sj.bjc.6603584.